China's first "cardiovascular health and nattokinase application expert guidelines" released

Release time:

2024-04-01

From March 22 to 24, 2024, the annual Wuhu Health Conference and the 8th China Chronic Disease Health Management and Big Health Industry Summit were grandly held in Hangzhou. At the meeting, my country's first ''Cardiovascular Health and Nattokinase Application Expert Guidelines "was released, and Academician Zhang Yuanting and a large number of experts, scholars and industries participated in the meeting. People's Daily, China Net, Life Times, Health Times, Sina Health, Phoenix Health and many other media have reported. Our company also participated in the five lakes health conference.

China's first "cardiovascular health and nattokinase application expert guidelines" released

NattokinaseBecauseWith thrombolysis, antihypertensive, anticoagulation and other functions, in2019was first written into expert advice, since then.More clinicians in our country, especially doctors in related departments such as heart, began to have a strong interest in nattokinase,And in clinical practice it is gradually included as one of the options for non-pharmacological intervention in cardiovascular disease.AlsoAs a starting point, nattokinase in China has entered a new period of promotion, and indirectly promote.It'sNattokinase ApplicationExpert GuidanceRelease after 5 years.《Cardiovascular Health and Nattokinase Application Expert Guide》Gathering a large number of clinical research conclusions and the consensus and wisdom of many medical experts, it opens a new path and new method for the non-drug precision nutrition intervention of cardiovascular and cerebrovascular health.

At the "Cardiovascular Health and Nattokinase Application Forum", Professor Wu Liuxin, Chairman of the Wuhu Health Conference, Professor Zhu Ling, Executive Chairman of the Conference, Chen Ning, Chief Physician of Hangzhou First People's Hospital, Dr. Tian Liyuan, Director of Research Department of Zhongguancun Xinzhiyuan Health Management Research Institute, Yuan Shengyuan, Director of Cardiovascular Health Management and Nattokinase Application Research Center, and Chen Zhiheng, Founding Director of Health Management Research Center of Central University, respectively conducted in-depth discussions around the expert guidelines issued.

Professor Wu Liuxin emphasized the importance of nattokinase in the keynote speech, and proposed that more applied research will be carried out in the future to promote the application of nattokinase in cardiovascular health management;In interpreting the guidelines, Professor Zhu Ling pointed out that it is essential to scientifically select nattokinase according to expert guidelines.;Dr. Tian Liyuan popularized the selection of nattokinase"Five look" principle: one look at the product certification, two look at the product dosage form, three look at the active content, four look at the zhuanli technology, five look at the research evidence. Wuhan Kang Lvda Biotechnology Co., Ltd. also participated in the nattokinase expert guidance forum.

Wuhan Kanglvda Biotechnology Co., Ltd.

Located in Wuhan Optical Valley Biological City, it is mainly engaged in the development and service of Bacillus biotechnology, and carries out the research and development of Bacillus breeding, metabolic regulation, fermentation process optimization, etc., and is at the forefront of the world in the field of Bacillus biotechnology. It has 12 national zhuanli authorizations, covering the main products of polyglutamic acid and the main preparation technology of natto powder.

Product indicators and specifications

Solemn Promise

This product Wuhan Kang Lvda Biological Technology Co., Ltd. unique zhuanli technology development and production, does not contain purine, does not contain vitamin K2, does not contain soy isoflavones.